TearScience® Announces New Pricing Strategy For Core LipiFlow® Technology Used For Treatment Of Dry Eye From Meibomian Gland Disease (MGD)

MORRISVILLE, N.C.--(BUSINESS WIRE)--TearScience, a privately held medical device company, has announced a 50% price cut, effective immediately, on the single-use activators used with the LipiFlow treatment platform for Meibomian Gland Disease (MGD). The move is just one component of an overall strategy to make the LipiFlow and LipiView® Technologies more accessible to Eye Care Professionals (ECPs), who can then, in turn, use them to evaluate and intervene earlier in MGD for the benefit of the m